Report: Eli Lilly settles patent suit with ScinoPharm

NEW YORK A popular drug maker has settled its patent suits with a Taiwan-based pharmaceutical company.

Eli Lilly & Co. and ScinoPharm Taiwan Ltd. said Thursday they have settled all patent lawsuits related to ScinoPharm's sales of the cancer drug Gemzar, the Associated Press reported.

In exchange for royalties, Lilly granted ScinoPharm a license to make and sell the drug in countries where Lilly's compound and method of use patents are not in force.

Gemzar (gemcitabine) is the Indianapolis company's fourth-best selling drug.